Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03719690
Title Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Kura Oncology, Inc.
Indications

oral squamous cell carcinoma

head and neck squamous cell carcinoma

nasopharynx carcinoma

laryngeal squamous cell carcinoma

paranasal sinus cancer

pharynx squamous cell carcinoma

Therapies

Tipifarnib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST